Background Quality of life (QoL) is one of the core outcome domains identified by the Harmonising Outcome Measures for Eczema (HOME) initiative to be assessed in every eczema trial. There is uncertainty about the most appropriate QoL instrument to measure this domain in infants, children and adolescents. Objectives To systematically evaluate the measurement properties of existing measurement instruments developed and/or validated for the measurement of QoL in infants, children and adolescents with eczema. Methods A systematic literature search in PubMed and Embase, complemented by a thorough hand search of reference lists, retrieved studies on measurement properties of eczema QoL instruments for infants, children and adolescents. For all eligible studies, we judged the adequacy of the measurement properties and the methodological study quality with the COnsensus-based Standards for the selection of health Measurement INstruments (COSMIN) checklist. Results from different studies were summarized in a best-evidence synthesis and formed the basis to assign four degrees of recommendation. Results Seventeen articles, three of which were found by hand search, were included. These 17 articles reported on 24 instruments. No instrument can be recommended for use in all eczema trials because none fulfilled all required adequacy criteria. With adequate internal consistency, reliability and hypothesis testing, the U.S. version of the Childhood Atopic Dermatitis Impact Scale (CADIS), a proxy-reported instrument, has the potential to be recommended depending on the results of further validation studies. All other instruments, including all selfreported ones, lacked significant validation data. Conclusions Currently, no QoL instrument for infants, children and adolescents with eczema can be highly recommended. Future validation research should primarily focus on the CADIS, but also attempt to broaden the evidence base for the validity of self-reported instruments.
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What's already known about this topic?
• Most eczema trials include the Infants' Dermatitis Quality of Life Index (IDQoL) or the Children's Dermatology Life Quality Index (CDLQI) as quality of life (QoL) measurement instruments.
• It is unclear which instruments are most appropriate to measure QoL in infants, children and adolescents with eczema.
What does this study add?
• Most QoL instruments for infants, children and adolescents with eczema are poorly validated, indicating a clear need for further validation work.
Affecting more than 10% of infants and children, eczema (synonyms: 'atopic eczema', 'atopic dermatitis') is one of the most common chronic diseases in children in many countries. [1] [2] [3] A high eczema prevalence is also observed in adolescence, 2 with a substantial risk of the disease persisting into adulthood. 4 Despite a multitude of treatment options, evidence-based decision-making based on systematic reviews and meta-analyses is hampered due to the heterogeneity of outcome measurement instruments used, particularly in randomized controlled trials. Therefore, the Harmonising Outcome Measures for Eczema (HOME) initiative (www.homeforeczema.org) aims to develop a core outcome set (COS) for use in all future eczema trials. A COS is a minimum set of outcomes that should be measured and reported in all clinical trials of a specific disease or trial population. 5 The core outcome domains suggested by the HOME initiative are clinical signs, symptoms, long-term control of flares and quality of life (QoL). [6] [7] [8] Following the HOME roadmap, 9 we performed a systematic review of the measurement properties of all instruments that were developed and validated to measure QoL in infants, children and adolescents with eczema. For adults, this step has already been completed. 10 
Material and methods

Protocol and registration
This systematic review was developed in accordance with the Preferred Reporting Items for Systematic Reviews and MetaAnalyses (PRISMA) statement. 11 A completed PRISMA checklist is available as an online appendix to this publication (see Appendix SA1; Supporting Information). The study protocol was published 12 and registered in the International Prospective Register of Systematic Reviews (PROSPERO): CRD42015023483.
Literature search
A systematic literature search in PubMed and EMBASE was conducted on 18 June 2015. The entire search strategy is shown in detail in the study protocol. 12 Hand searching of the PROQOLID database (http://www.proqolid.org) and reference lists of included studies and key articles on QoL in infants, children and adolescents with eczema complemented the systematic search.
Eligible studies
We applied the eligibility criteria presented in the protocol. 12 Briefly, the study population of eligible development and validation studies of dermatology-or eczema-specific QoL instruments had to consist of at least 50% of patients with eczema younger than 16 years of age, or studies had to present subgroup analyses for this patient group.
Content comparison
The content of the included instruments was compared at the content domain level based on information from the original development paper.
Assessment of the methodological quality of included studies
We used the COnsensus-based Standards for the selection of health Measurement INstruments (COSMIN) checklist to judge the methodological quality of the included studies (www.cosmin.nl). [13] [14] [15] [16] This checklist consists of 5-18 items per measurement property covering methodological standards; the compliance with these standards is rated on a four-point rating scale ('poor', 'fair', 'good', 'excellent'). The lowest rating for any item pertaining to a certain measurement property determines the overall rating for this measurement property.
Assessment of measurement properties and further characteristics of quality of life instruments
With the exception of criterion validity, all measurement properties from the COSMIN checklist were evaluated in this systematic review. Where available, interpretability and feasibility data were collected. Because we view them as distinct instruments, different language versions of the same questionnaire were considered separately throughout this review except for content comparison and instrument characteristics.
Assessment of the adequacy of the measurement properties
To evaluate the adequacy of the investigated measurement properties, we applied the corresponding predefined criteria recommended by the COSMIN group in a slightly modified version (see Table SA1 in Appendix SA2; Supporting Information). 17, 18 The specific changes we made to these criteria are explained in the protocol. 12 Where studies used item response theory (IRT) methods in the assessment of measurement properties instead of the development of measurement instruments, we assessed the adequacy and methodological quality of internal consistency, construct validity, structural validity and cross-cultural validity.
Best-evidence synthesis
Findings on the same instrument from multiple studies were synthesized if the characteristics of the included studies were sufficiently similar, the results did not show considerably different or conflicting findings and the methodological quality of the included studies was adequate. 19 Criteria for best-evidence synthesis are found in Table SA2 (in Appendix SA2; Supporting Information).
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Generating recommendations for the use of quality of life measurement instruments for eczema
Depending on the adequacy of each instrument and the methodological quality of the included studies, a standardized recommendation for usage and necessary future validation work was made for each investigated instrument. Four categories of recommendation were made:
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A QoL measurement instrument meets all requirements and is recommended for use. B QoL measure meets two or more adequacy criteria, but performance in all other required adequacy criteria is unclear, so that the outcome measure has the potential to be recommended in the future depending on the results of further validation studies. C QoL measure has low adequacy in at least one required adequacy criterion (≥ 1 rating of 'minus') and therefore is not recommended to be used anymore. D QoL measure has (almost) not been validated. Its performance in all or most relevant adequacy criteria is unclear so that it is not recommended to be used until further validation studies clarify its adequacy.
Finally, we aimed to identify one best (currently available) instrument to assess QoL in infants, one best (currently available) instrument to assess QoL in children, and one best (currently available) instrument to assess QoL in adolescents with eczema.
Results
Seventeen articles were included (Fig. 1) . [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] One paper complying with the inclusion criteria presented only summary information, making analyses of the evaluated questionnaires and measurement properties impossible; the paper was consequently excluded. 38 Another paper containing data on the content validity of the Childhood Impact of Atopic Dermatitis (CIAD) did not formally meet the inclusion criteria and was thus excluded. 39 However, read in conjunction with the eligible development article of the CIAD, 34 information on content validity could be extracted from that excluded paper and was therefore considered for this review. Most included studies reported on the Children's Dermatology Life Quality Index (CDLQI, n = 6) 22, [29] [30] [31] 33, 36 and the Infants' Dermatitis Quality of Life Index (IDQoL, n = 6). 21, 24, 25, 29, 32, 37 Three studies evaluated the Childhood Atopic Dermatitis Impact Scale (CADIS) 26, 27, 35 and two studies assessed the DISABKIDS Atopic Dermatitis Module (DISABKIDS-ADM). 23, 28 Information on the CIAD was available from two studies, 34, 39 but only one of them met the inclusion criteria. 34 A comparison of the content covered by these five instruments is presented in Table SA3 (in Appendix SA2; Supporting Information). The CDLQI and the IDQoL are the most similar in content out of the five instruments. Table 1 shows other general characteristics of the included instruments. The CADIS, CIAD and IDQoL are proxy-reported, whereas the CDLQI is completed by the children themselves. The questionnaire DIS-ABKIDS-ADM is available both in a self-and a proxy-reported version. Only the CDLQI is a dermatology-specific instrument; all others are eczema-specific. The lowest number of items in a questionnaire is seven, the highest 45. Four of the five questionnaires apply a 4-or 5-point Likert scale; only the CIAD uses a dichotomous response format.
Characteristics of the included studies
An overview of settings and study populations in the included studies is shown in Table 2 . Most studies were conducted in secondary/tertiary care settings in Europe. Sample sizes ranged from eight to 370 patients.
Validity of the instruments and recommendations
In total, we were able to rate the methodological quality of 84 measurement properties. Two measurement properties (2%) had good, 18 (21%) had fair and 64 (76%) had poor methodological quality. Detailed results for every instrument and study investigated in this systematic review can be found in Supplementary Tables S1-S80 (found in the Detailed Results SR1; Supporting Information). Table SA4 (in Appendix SA2; Supporting Information) shows the number of studies assessing the different measurement properties of each included proxy-reported QoL instrument. The results of best-evidence synthesis and the degree of recommendation for each proxy-reported instrument are found in Table 3 . There was no instrument for which all relevant measurement properties have been investigated. Hence, there was also no instrument that fulfilled all prespecified requirements of truth, discrimination and feasibility.
Proxy-reported instruments
With Cronbach's a ranging from 0Á76 to 0Á93 for its subscales, internal consistency of the U.S. version of the CADIS was found to be adequate. 26 Most language versions of the CIAD also demonstrated good internal consistency, with Cronbach's a values between 0Á72 and 0Á85. 34 For the other instruments, internal consistency assessment was either conducted methodologically poorly or was not done at all. Measurement error was not investigated for any of the proxyreported instruments included. Good reliability was shown for the U.S. version of the CADIS, with intraclass correlation coefficients (ICC) of 0Á89-0Á95 for the domain scores and 0Á96 for the total score between the two administrations. 27 An ICC of 0Á89 was found for the Dutch IDQoL, proving this instrument to be adequately reliable. 37 While three language versions of the CIAD obtained an indeterminate rating for reliability, there was either no evidence or evidence only from methodologically poor studies for the other instruments. Data on content validity could be extracted for the U.S. version of the CADIS, the U.K. version of the IDQoL and all language versions of the CIAD. However, all content validity assessments were conducted methodologically poorly. No clear rating could be assigned for the IRT methods used to investigate structural validity of the U.S. version of the CIAD. and 0Á68 with the Dermatitis Family Impact were found for the long-version Italian CADIS. 35 Discriminative validity of the U.S. version of the CADIS was proven adequate because the instrument could differentiate patients according to severity as measured by the SCORing Atopic Dermatitis (SCORAD) index. 27 Convergent validity of the U.K. version of the IDQoL was assessed in a study of fair methodological quality, but resulted in an indeterminate adequacy rating as only correlations with unrelated constructs were determined. 32 Evidence on hypothesis testing for the remaining questionnaires was available from methodologically poor studies only. 21, 24, 28, 29, 34, 37 Likewise, we could not draw a conclusion on cross-cultural validity, which was assessed for the long version of the Italian CADIS and four language versions of the CIAD, due to poor methodological study quality. 34, 35 Responsiveness in patients with eczema was investigated for only three questionnaires, but these assessments were of poor methodological quality. 25, 27, 32, 34 Values for the minimal important change (MIC), the minimal important difference (MID) or validated banding systems are not available for the IDQoL. 40 Evidence from several included validation studies suggests that the IDQoL does not exhibit floor and ceiling effects (i.e. ≥ 15% of patients having the lowest/highest possible score). 24, 29, 32, 37 We could not find information on the interpretability of the other proxyreported questionnaires. Completion time of the CADIS amounted to approximately 6 min in one study. CADIS, Childhood Atopic Dermatitis Impact Scale; CDLQI, Children's Dermatology Life Quality Index; CIAD, Childhood Impact of Atopic Dermatitis; DISABKIDS-ADM, DISABKIDS Atopic Dermatitis Module; IDQoL, Infants' Dermatitis Quality of Life Index; ND, not described. a 'Proxy-reported' means that the (primary) caregiver of an infant fills in a questionnaire that assesses the quality of life of the infant. Proxyreported instruments are often used with infants and younger children because they cannot report on their quality of life themselves due to their inability to read and a lack of understanding. b 'Self-reported' instruments are used with older children and adolescents. These question- No description given regarding which language versions were tested in the European validation study. Table 4 . There was no instrument for which all relevant measurement properties have been investigated. Hence, there was also no instrument that fulfilled all prespecified requirements of truth, discrimination and feasibility. Internal consistency assessments were available for four included self-reported QoL instruments, but all were conducted methodologically poorly. Measurement error was not evaluated for any self-reported instrument included. Both the Malay and the Mexican Spanish CDLQI were assigned an indeterminate rating for reliability, whereas this measurement property was not investigated for any other included self-reported instrument.
Self-reported instruments
Content validity was investigated only for the unknown language version of the DISABKIDS-ADM, but the methodological study quality was poor. 23 Information on structural validity of the included self-reported instruments was not available. Data on hypothesis testing was available for all instruments except the unknown language version of the DISABKIDS-ADM. We found an intermediate rating for discriminative validity of the Swedish CDLQI because the instrument was able to differentiate patients according to age, but could not distinguish patients with eczema only from patients with eczema and another allergic comorbidity. 29 The assessments of construct validity of all other questionnaires were of poor methodological quality. Cross-cultural validity was not assessed for any self-reported QoL instrument included. An investigation of responsiveness was available for the Danish CDLQI only, but was conducted methodologically poorly. 30 Little information on interpretability is available for the selfreported QoL instruments. No floor and ceiling effects were found for the CDLQI in an analysis of 50 Swedish children with eczema. 29 Similarly, the CDLQI showed no floor and ceiling effects in the 47 children participating in its development study. 31 A recent meta-analysis provides an overview of CDLQI scores in different conditions, enabling comparisons of scores of patients with eczema with those of patients suffering from other diseases and helping to interpret patients' CDLQI scores. 41 Values for the MIC/MID for the CDLQI in patients with eczema, as well as interpretability data for the DISAB-KIDS-ADM, could not be found.
Discussion
This systematic review assessed the measurement properties of five different QoL instruments for use in infants, children and adolescents with eczema. None of these instruments complied with all prespecified filter criteria of truth, discrimination and feasibility, clearly indicating that more validation work is required. The strengths of this systematic review include a registered and published protocol, the application of a validated, precise search filter 42 and of predefined eligibility criteria, and the use of the COSMIN checklist [13] [14] [15] [16] to judge the methodological quality of the included studies. Every step of the review process was carried out by at least two reviewers. Furthermore, one reviewer (D.H.) was involved in every step of the review to ensure consistency among the participating reviewers. Discrepancies were resolved by frequent discussions within the whole team. A limitation of this review is the fact that only PubMed and Embase were searched. A thorough hand search of reference lists of included studies, important reviews and the information on the participating health service providers was presented, which is why it was not possible to group these study populations into one of the three categories of community, primary care or secondary/tertiary care. PROQOLID database retrieved 10 articles of interest not found in our initial systematic search, three of which were judged eligible and included. Another limitation may be that we could not consider responsiveness results of the CIAD obtained in the whole European sample because the paper provided no corresponding country-specific data. Also, information on discriminative validity of the CIAD could not be considered because the specific P-values were not presented by McKenna et al.
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Of all the instruments reviewed, only the U.S. version of the CADIS 26 reached category B, hence having the potential to be recommended in the future depending on the results of further validation studies. All other questionnaires were placed in category D; their future use cannot be endorsed until further validation data is available. The CADIS, intended for use in patients with eczema 0-6 years of age, is an internally consistent, reliable questionnaire with adequate construct validity. Its conceptual framework is based on a literature review and directed focus sessions with experts and parents. Compared with the other included instruments, the CADIS is unique in that it assesses both the QoL of the affected infant or child and the QoL of their parents. Although the instrument provides a total score, separate scores for the domains relating to the child's QoL can also be calculated. Results from both the infant-or child-related domains and the parent-related domains were considered for this systematic review. The 45-item questionnaire was completed quickly. A disadvantage of the CADIS is that only three validated language versions of the instrument are currently available, with a validation study of a Spanish version being prepared for publication (personal communication; see reference list for details). 43 The validation article of the Japanese CADIS version, recently published, 44 was not investigated in this systematic review because it was not yet available when our systematic review was conducted. It will be taken into account in the first update to this systematic review. Measurement error and structural validity of the CADIS have not yet been investigated. Moreover, future studies of improved methodological quality should look at content validity, cross-cultural validity, responsiveness and interpretability of the CADIS. The major finding of this systematic review is that nearly all existing QoL instruments for infants, children and adolescents with eczema are lacking significant validation data and were hence classified in category D. One reason for this is that 76% of the measurement properties were investigated in a methodologically poor manner, compared with 25% in our preceding systematic review assessing the measurement properties of adult eczema QoL instruments. 10 Part of this difference can be attributed to a stricter approach in judging whether hypotheses were formulated a priori when assessing hypothesis testing and responsiveness (item 4 in COSMIN box F, item 8 in COS-MIN box I) in this review compared with the afore-mentioned review of adult eczema QoL instruments. However, only 16 of the 32 COSMIN boxes of hypothesis testing and responsiveness rated as 'poor' in this systematic review would obtain a better COSMIN rating if a less strict approach concerning hypotheses formulation were applied, still leaving 57% methodologically poorly investigated measurement properties in total. This result suggests that the methodological study quality is indeed worse than in the previous review on adult eczema QoL instruments. In addition to insufficient or methodologically poor validation of most instruments included, interpretability data is also lacking. A MID of 2Á5 points on the CDLQI has been found in 45 but corresponding data for patients with eczema do not exist. Similarly, a banding system to help in interpreting CDLQI scores has been developed, 46 but the study did not meet our eligibility criteria because it reported on general dermatology patients in abstract form only. Interpretability in patients with eczema is an important topic that future validation studies should address. Only two of the five included instruments are self-reported by the affected children. While proxy-reported measures, including the CADIS, may be particularly useful in infants and younger children, they are not suitable for older children and adolescents. As both the CDLQI and the DISABKIDS-ADM were placed in category D, there is currently no self-reported QoL instrument for paediatric eczema that can be recommended for use. CDLQI and DISABKIDS-ADM are also intended for use in adolescents. However, it has been argued that factors influencing adolescents' QoL are fundamentally different from those observed in children and adults, leading to the development of the adolescent-specific Skindex-Teen. 47 The development study of this questionnaire was not eligible for this review, though. Future validation studies of self-reported QoL instruments should therefore investigate whether they are suitable for adolescents with eczema as well, or if separate instruments for this age group are needed. Currently, only the CADIS has the potential to be recommended for use depending on the results of further validation studies. These validation studies should include all existing language versions of the CADIS and specifically examine measurement error, content validity, structural validity, cross-cultural validity, responsiveness and interpretability. If these studies find favourable measurement properties of the CADIS, it should be translated and validated in more languages to increase international applicability. As the IDQoL is the QoL instrument most often used in eczema trials involving infants, 48 it seems also advisable to undertake further validation work for this questionnaire. Additionally, future validation research should focus on self-reported QoL instruments for children and adolescents with eczema included in this review (CDLQI and DISABKIDS-ADM).
For the time being, as none of the investigated QoL instruments can be highly recommended, we suggest using the proxyreported CADIS for infants and younger children with eczema until formal consensus is reached by the HOME initiative. For older children and adolescents with eczema, there is currently no valid, reliable and feasible self-reported instrument. Trials in this age group should include the QoL instrument that in their authors' opinion is best suited for children and adolescents with eczema. In older adolescents, the two QoL instruments for adults with eczema placed in category B in a previous systematic review, 10 the Quality of Life Index for Atopic Dermatitis (QoLIAD) 49 and the Dermatology Life Quality Index (DLQI), 50 may be applicable.
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